Zeo ScientifiXZEOX 50 Gross Margin % is 79.62% as of Apr. 2026, which is 3% below its 10-year median of 82.20. GuruFocus rates ZEOX with a GF Score™ of 50/100 and a GF Value™ of $2.67 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 737 Biotechnology companies, Zeo ScientifiX ranks better than 73.95% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Zeo ScientifiX had a gross margin of 79.62% for the quarter that ended in Apr. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Zeo ScientifiX Gross Margin % Related Terms
Zeo ScientifiX Gross Margin % Historical Data
* Premium members only.
The historical data trend for Zeo ScientifiX's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZEOX vs LNAI, GDTC, HOOK: Gross Margin % Comparison
For the Biotechnology subindustry, Zeo ScientifiX's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zeo ScientifiX Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zeo ScientifiX's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Zeo ScientifiX's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Zeo ScientifiX (ZEOX) has a Gross Margin % of 79.62% as of Apr. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Zeo ScientifiX and its competitors. This is near median its historical median of 82.20. Over the past decade, Zeo ScientifiX's Gross Margin % has ranged from 48.65 to 90.23. According to the industry distribution chart, Zeo ScientifiX ranks #192 out of 737 companies in the Biotechnology industry, placing it in the top 26.1%.
Is Zeo ScientifiX's Gross Margin % too high?
Zeo ScientifiX's current Gross Margin % of 79.62% is near median its 10-year median of 82.20. Over the past 10 years, this metric has ranged from a low of 48.65 to a high of 90.23. The Biotechnology industry median Gross Margin % is 60.92. Zeo ScientifiX's value of 79.62% is 30.7% above this industry median. Based on the distribution chart, Zeo ScientifiX ranks #192 out of 737 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zeo ScientifiX has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zeo ScientifiX's Gross Margin % compare to LNAI and GDTC?
According to the Biotechnology industry distribution chart, Zeo ScientifiX ranks #192 out of 737 companies for Gross Margin %. This puts Zeo ScientifiX in the upper half of its industry. The industry median Gross Margin % is 60.92. Zeo ScientifiX's value of 79.62% is 30.7% above this benchmark. Historically, Zeo ScientifiX's own Gross Margin % has ranged from 48.65 to 90.23 over the past decade. While the company's 10-year median is 82.20 vs. the industry median of 60.92, Zeo ScientifiX has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zeo ScientifiX's current Gross Margin % of 79.62% is 30.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Zeo ScientifiX and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zeo ScientifiX's current Gross Margin % is 79.62%, which is near median its own 10-year median of 82.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zeo ScientifiX stock overvalued right now?
Based on GuruFocus' analysis, Zeo ScientifiX (ZEOX) is currently considered Possible Value Trap. The stock's GF Value™ is $2.67, compared to a current price of $1.75 — trading 34.5% below its estimated fair value. The current Gross Margin % is 79.62%, which is near median its 10-year median of 82.20 and 30.7% above the Biotechnology industry median of 60.92. Zeo ScientifiX's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Zeo ScientifiX (ZEOX), the current Gross Margin % is 79.62% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zeo ScientifiX (ZEOX) Overvalued in 2026?
Based on GuruFocus' analysis, Zeo ScientifiX stock appears to be undervalued.
The current stock price of $1.75 is trading 34.5% below its estimated GF Value™ of $2.67.
GuruFocus considers Zeo ScientifiX to be Possible Value Trap.
Key valuation signals for ZEOX:
Gross Margin %: 79.62% (near median its 10-year median of 82.20)
GF Value™: $2.67 vs. price of $1.75 (34.5% below fair value)
Industry Position: 30.7% above the Biotechnology median (#192 of 737)
No single metric tells the full story. See the ZEOX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zeo ScientifiX Inc is a clinical-stage biopharmaceutical company located inside Nova Southeastern University's Collaborative Center for Research in Davie, Florida. The Company is a clinical-stage biopharmaceutical company principally focusing on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicine. The Company's proprietary products, including Zofin, are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles and Patient Pure X (PPX ), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient's own peripheral blood (RAAM Products).
50GF Score
Get the complete analysis for ZEOX
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZEOX has been successfully added to your 
